-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PIPE-791 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocrelizumab in Autoimmune Encephalitis (Post-Infectious)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocrelizumab in Autoimmune Encephalitis (Post-Infectious) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocrelizumab in Autoimmune Encephalitis (Post-Infectious) Drug Details: Ocrelizumab (Ocrevus) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-101 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Parkinson's Disease Drug Details: MP-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Amyotrophic Lateral Sclerosis Drug Details: DNL-788 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-101 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Drug Details: Fenebrutinib (GDC-0853,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Systemic Lupus Erythematosus Drug Details: CC-97540 is under...